Exemestane in Reducing Breast Density in Postmenopausal Women at Risk for Breast Cancer

NACompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

August 1, 2001

Primary Completion Date

November 16, 2007

Study Completion Date

February 10, 2009

Conditions
Breast Cancer
Interventions
DRUG

exemestane

exemestane 25 mg once daily x 1 year

DRUG

Placebo

placebo once daily x 1 year

Trial Locations (12)

32224

Mayo Clinic - Jacksonville, Jacksonville

55905

Mayo Clinic Cancer Center, Rochester

02114

Massachusetts General Hospital Cancer Center, Boston

02115

Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston

02215

Beth Israel Deaconess Medical Center, Boston

Brigham and Women's Hospital, Boston

43210-1240

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University, Columbus

02860

Memorial Hospital of Rhode Island, Pawtucket

L8V 5C2

Margaret and Charles Juravinski Cancer Centre, Hamilton

P7B 6V4

Northwestern Ontario Regional Cancer Care at Thunder Bay Regional Health Sciences Centre, Thunder Bay

M5G 2M9

Princess Margaret Hospital, Toronto

H2L-4M1

Centre Hospitalier de l'Universite de Montreal, Montreal

Sponsors
All Listed Sponsors
lead

NCIC Clinical Trials Group

NETWORK